ReviewInternational journal of retina and vitreous2026
Diagnostic value of congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis: a systematic review.
Review in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital hypertrophy of the retinal pigment epithelium (CHRPE) has been proposed as a phenotypic marker of familial adenomatous polyposis (FAP). This systematic review aimed to evaluate the evidence regarding the association between CHRPE and FAP and to determine the potential clinical utility of CHRPE for the early identification of individuals with adenomatous polyposis coli (APC) mutations.
methodsA systematic search of PubMed/MEDLINE, Embase, and Web of Science from inception to August 2025 in accordance with PRISMA guideline and a PROSPERO-registered protocol was done. Studies reporting CHRPE in individuals with confirmed or suspected FAP or at-risk first-degree relatives were identified. Data extraction and quality assessment using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool were performed independently by two reviewers. Due to substantial heterogeneity in CHRPE definitions, diagnostic criteria, population characteristics, and APC mutation testing methods, quantitative pooling was not considered appropriate and findings were synthesized qualitatively.
resultsForty-three studies were included. CHRPE demonstrated consistently high specificity for FAP and APC mutation carriage across most studies. Sensitivity ranged from 40% to 100% in affected individuals and from 57% to 100% in at-risk relatives, while specificity ranged from 58% to 100%, depending on diagnostic criteria. Stricter definitions incorporating lesion multiplicity and bilaterality improved specificity at the expense of sensitivity.
conclusionCHRPE is associated with FAP but demonstrates variable diagnostic performance across studies. Its clinical utility as a standalone screening marker is limited by heterogeneous diagnostic definitions. Standardized diagnostic criteria and prospective studies using contemporary genetic testing are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.